Safety and clinical efficiency of a long-term complete blockade of renin-angiotensin-aldosterone system in patients with chronic obstructive pulmonary diseases

Terapevticheskii Arkhiv

Volumn 72, Issue 10, 2000, Pages 52-56

  Arutyunov, G P ^a   Korsunskaya, M I ^a   Chernyavskaya, T K ^a   Vershinin, A A ^a   Rozanov, A V ^a   Balanina, N O ^a  

^a NONE

Author keywords

Blockade; Chronic obstructive pulmonary diseases; Efficiency; Renin angiotensin aldosterone system; Safety

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART CONTRACTION; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LUNG WEDGE PRESSURE; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SAFETY; TREATMENT OUTCOME;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PROSPECTIVE STUDIES; PULMONARY WEDGE PRESSURE; RENIN-ANGIOTENSIN SYSTEM; SAFETY; TREATMENT OUTCOME; VENTRICULAR FUNCTION, RIGHT;

EID: 17144453759     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Weiz E. K., Reeves J. T. Pulmonary hypertension. Mt Kisco, (NY): Futura; 1984.
2. Weizenblum E. Long-term course of pulmonary arterial pressure in chronic obstructive lung disease. Am. Rev. Resp. Dis. 1984; 130: 993-1009.
3. Lipworth B. J., Dagg K. D. Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed. Chest 1994; 105: 1360-1364.
4. Falter M. O., Kiblawi S. S. O., Strawbridge R. A. et al. Study on plasma vasoproxin and the renin-angiotensin-aldosterone system in chronic obstructive lung disease. J. Lab. Clin. Med. 1977; 90: 373-380.
5. Farber M. O., Robens L. R., Weinberger M. H. et al. Abnormalities of sodium and water handling in chronic obstructive lung disease Arch. Intern. Med. 1982; 142: 1326-1330.
6. Archer S. L., Weir E. K. Mechanism in hypoxic pulmonary hypertension. In: Pulmonary circulation: advances and contriversies. Amsterdam: Elsevier; 1989. 87-107.
7. Pitt B., Zannad F., Remme W. J. et al. The effect of spirinolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1000; 341: 709-717.
8. Barnes P. J. New therapies for chronic obstructive pulmonary disease. Thorax, 1998; 53 (2): 137-147.
9. Work Group of Nifedi pin on patients with pulmonary hypertension. Am. J. Cardiol. 1993: 71: 1475-1481.
10. Kiely D. G., Cargill R. I., Lipworth B. J. Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade. Cardiovasc. Res. 1995; 30: 875-880.
11. Raff H., Levy S. A. Renin-angiotensin-aldosteron and ACTH-cortisol control during hypoxemia and exercise in patients with chronic obstructive lung disease. Am. Rev. Respir. Dis. 1986; 133: 369-399.
12. Kiely D. G., Cargill R. I., Whelldon N. M. et al. Haemodynamic and endocrine effects of type I angiotensin II receptor blockade in patients with hypoxemic cor pulmonale. Cardiovasc. Res. 1997; 33: 201-208.
13. Magee F., Wright J. L., Wiggs B. R. et al. Pulmonary vascular structure and function in chronic obstructive lung disease. Thorax 1988; 43: 183-189.
14. MacNee W., Watten C. O., Flenley D. C., Muir A. D. The effects of controlled oxygen therapy on ventricular function in patients with stable and decompensated cor pulmonale. Am. Rev. Respir. Dis. 1988; 137: 1289-1295.
15. Cargill R. G., Lipworth B. J. Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans. Chea 1996; 1 (2): 424-429.
16. Boschetti E., Tantucci C., Cocchieri M. et al. Acute effects of captopril in hypoxic pulmonary hypertension. Respiration 1985: 48: 296-302.
17. Takada K., Hayashi M, Takohashi K., Yasui S. Acute effects of oral captopril on haemodynamics in patients with cor pulmonale. Jpn. Circ. J. 1986; 50: 1055-1061.
18. Bertoli L., Cicero S. L., Busnardo I. et al. Effects of captopril on haemodynamic and blood gases in chronic obstructive lung disease with pulmonary hypertension. Respiration 1986: 49: 251-256.
19. Zielinski J., Hawrilkiewicz I., Gorecka D. et al. Captopril effects on pulmonary and systemic haemodynamics in chronic cor pulmonale. Chest 1984; 90: 562-565.
20. Burke C. M., Harte M., Duncan J. et al. Captopril and domiciliary oxygen in chronic airflow obstruction. Br. Med. J. 1985; 290: 1251.
21. Eisen H. J., Pina I. J., Mather P. et al. Improvment in pulmonary hypertension refractory to standard vasodilatators using the angiotensine II receptor antagonist losartan in patients with severe congestive heart failure. Circulation. 1996; 94 (suppl. 8): 1289-1289.
22. Laurent S., Vanhoutte P., Cavero I. et al. The arterial wall: a new pharmacological and therapeutic target. Clin. Pharmacol. 1996; 10 (3): 243-257.
23. Crotier M. D., Ikrom J. D. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91: 691-697.
24. Mironnrau J. Calcium channel antagonists effects of spironolactone and aldosterone antagonist. Am. J. Cardiol. 1990; 38: 1709-1715.